Mr. Jose Tempero reports

TILRAY MEDICAL ANNOUNCES SCIENTIFIC STUDY ON MEDICAL CANNABIS FOR PATIENTS OVER AGE 50

Tilray Medical, a division of Tilray Brands Inc., has released a scientific publication titled Medical Cannabis for Patients Over Age 50: A Multi-Site, Prospective Study of Patterns of Use and Health Outcomes. The medical cannabis in older patients study (MCOPS) is a multisite, prospective, observational study examining the real-world impact of medical use on patients over the age of 50 and under the guidance of a health care provider.

The MCOPS study comprised 299 participants with an average age of 66.7 years and 62.2 per cent of respondents identified as female. Approximately 90 per cent of patients used medical cannabis to treat pain-related conditions such as chronic pain and arthritis. This study presents to the medical and scientific community the impact of medical cannabis on health outcomes, with a focus on pain, sleep and quality of life.

Under medical cannabis guidance and care, the MCOPS shows correlation with improvements in pain scores, sleep and quality of life in a still growing subset of patients. A significant reduction of co-medication was observed, indicating that the treatment with medical cannabis can be a cost-effective option for this population.

Jose Tempero, Tilray's medical director, stated, "Our involvement in this initiative underscores our unwavering commitment to advancing medical research and highlights our dedication to providing products that supports the findings to the comprehensive research that bring us one step closer to unlocking the full therapeutic potential of medical cannabis, especially reinforcing its role as a treatment option for an aging population."

Tilray Medical's mission is to continue transforming lives and fostering dignity for patients in need through access to medical cannabis, and today is a leading provider of European Union good manufacturing process certified medical cannabis products in over 20 countries with a comprehensive portfolio of tetrahydrocannabinol and cannabidiol products. Tilray has supported medical trials globally, across Europe, Canada, the United States, Australia and Latin America, studying the efficacy of medical cannabis as a treatment for indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, posttraumatic stress disorder, and alcohol use disorders.

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers and governments, in 20 countries and across five continents.

About Tilray Brands Inc.

Tilray Brands is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is changing people's lives for the better -- one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body and soul while invoking well-being. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and well-being through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray's unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.